NewslettersPulmonary Cell NewsG1 Therapeutics Announces Investigator Initiated Study of Trilaciclib and Lurbinectedin in Patients with Extensive Stage Small Cell Lung CancerBy Jamie Kang - October 26, 20220251G1 Therapeutics, Inc. announced that it is supporting a Phase II investigator-initiated study of trilaciclib and lurbinectedin in patients with extensive stage NSCLC.[G1 Therapeutics, Inc.]Press Release